Wolwo Pharma(300357) 西南证券·2024-11-01 07:35Investment Rating - The report maintains a "Buy" rating for the company [3][4]. Core Views - The company reported a revenue of 730 million yuan for the first three quarters of 2024, representing an increase of 8.4% year-on-year, with a net profit attributable to shareholders of 270 million yuan, up 0.8% [3][4]. - The core product, dust mite drops, showed steady growth, with Q3 revenue reaching approximately 290 million yuan, a 4.3% increase, benefiting from the autumn sales peak [3][4]. - The company is expanding its product pipeline, with the clinical trial application for the dust mite film agent accepted by the National Medical Products Administration, which could enhance its market position if approved [4]. Financial Summary - For 2024, the company expects net profits of 350 million yuan, 430 million yuan, and 500 million yuan for the years 2024, 2025, and 2026, respectively, with corresponding dynamic PE ratios of 36x, 29x, and 25x [4][7]. - The projected revenue for 2024 is 928.77 million yuan, with a growth rate of 9.5%, and for 2025 and 2026, revenues are expected to be 1.11 billion yuan and 1.34 billion yuan, reflecting growth rates of 19.41% and 20.63% respectively [4][7]. - The report indicates that the company's sales expenses, management expenses, and R&D expenses for the first three quarters were 270 million yuan, 50 million yuan, and 90 million yuan, accounting for approximately 37.1%, 7.2%, and 12% of revenue, respectively [3][4].